VIRAL INACTIVATION METHOD

Abstract: The invention involves the use of supercritical or near-critical fluids for the inactivation of viruses, especially enveloped or lipid protected viruses, viral-like particles and other pathogens in any matrix, but preferably in solutions containing biologically active proteinaceous products of natural or genetic engineering origin or in semi-solid or solid support matrices which are thermally labile or sensitive to conventional viral inactivation techniques. Novel apparatus also are provided.

Description: VIRAL INACTIVATION METHOD Field of Invention This invention relates to methods and apparatus for the inactivation of viruses using supercritical fluids. Prior Art •Infectious viruses, unless inactivated, can be readily transmitted from biological products derived from human plasma as well as reco binant-DNA and monoclonal antibody sources. The hepatitis B virus (HBV) as well as the agents of non-A and non-B hepatitis (NANBHV) have plagued patients, physicians and manufacturers for many years. In recent years, the human immunodeficiency virus (HIV) — the etiologic agent of acquired immunodeficiency syndrome (AIDS) — has become a very serious and epidemic problem. In several instances, coagulation factor concentrates have transmitted HIV to hemophiliacs, some of whom have subsequently developed AIDS (an estimated 65 % of the 20,000 hemophiliacs in the United States are infected with HIV, Wall Street Journal, 12/27/90). orgenthaler, a leading researcher in this field, states in his preface to Viral Inactivation in Plasma Products (1989) that: "Clearly, there is a need for methods that inactivate viruses in blood, without causing harm to the components intended for therapeutic use." Viral inactivation of recombinant-DNA products is still a major and active concern for the biotechnology and pharmaceu ical industries as well as the regulatory agencies. The FDA in Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use states that: "It is strongly recommended that validated procedures ... which remove and/or inactivate viruses and DNA if present be employed during purification... " For reasons of safety and public health, the quest is to discover and develop processes for inactivating viruses without denaturing the biologically active products which are . commonly labile and quite sensitive to conventional viral inactivation techniques. A number of approaches have been employed for the inactivation of viruses in therapeutic proteins derived from human plasma and other biologically active raw materials. Some of these approaches include: heating or pasteurization; chemical inactivation agents; ultraviolet (UV) and gamma irradiation; solvent extraction of essential lipids; neutralization with specific antibodies; and removal by various fractionation techniques. Several heat treatment methods have been invented to inactivate viruses without adversely affecting the biological activity of particular proteins. Most of these methods require the use of stabilizers to protect the proteins or require the heat treatment of the materials in their lyophilized state. Fernandez et a ' l . (U.S. Pat. No. 4,440,679) utilize carbohydrate stabilizers for the pasteurization of Factor VIII which is a very thermally labile plasma protein. Reubenstein (U.S. Pat. No. 4,456,590) shows that Factor VIII can be pasteurized at 60C for 10 hours if first lyophilized and Thomas in U.S. Pat. No. 4,495,278 shows the same for Factor IX. Mitra et al . (U.S. Pat. No. 4,762,714) show viral inactivation in an immune globulin product by controlling conditions of pH, temperature and time. Feldman et al. (U.S. Pat. No. 4,876,241) teach a method of stabilizing biological and pharmaceutical products with mixtures of sugar and sugar alcohols with salts of sulfate and acetate prior to thermal inactivation of viral and bacterial contaminants. The current standard for rendering human serum albumin free from hepatitis virus (both HBV and NANBHV) is pasteurization at 60C for 10 hours. High concentrations of stabilizers (such as citrate, sucrose and caprylate) are typically used to protect biological activity during pasteurization. Plasma fractions such as Factor VIII can also be pasteurized in the lyophilized state which requires heating the plasma powder at 60C in the presence of stabilizers for more than 72 hours. The major problems with pasteurization are: long processing times; inactivation of plasma proteins and fractions; and the use of high concentrations of stabilizers which must be removed before therapeutic use (stabilizers also tend to protect the viruses as well as the proteins, thereby requiring longer and harsher treatment conditions) . Recently, Charm et al. in "High Temperature - Short Time Heat Inactivation of HIV and other Viruses in Human Blood Plasma," supported in part by NHLBI Grant No. HL41221 to the New York Blood Center, Nov. 16, 1990 and accepted for publication in Vox Sanguinis, 1991 have reported a high temperature-short time (HTST) heat inactivation method for HIV and other viruses in human blood plasma without the use of stabilizers or freeze-drying. While the inactivation data is quite encouraging, further studies are required including the validation of hepatitis B and hepatitis C virus inactivation. The HTST technique, under conditions required to inactivate certain viruses, may be burdened by significant loss of biological activity. Additionally, this microwave technique may not be able to handle very viscous materials and may not be very scalable. HTST equipment will require the use of very small diameter tubes in order to achieve rapid-heat up rates and short residence times necessary- for maintaining protein integrity. Chemical methods to inactivate viruses have been used by themselves or in combination with other physical separation methods: copper phenathroline and related compounds (Lembach, U.S. Pat. No. 4,534,972); tri-n-butyl phosphate and related compounds (Horowitz, U.S. Pat. No. 4,481,189); sodium caprylate in combination with heat and amino acids (Naito et al. , U.S. Pat. No. 4,446,134); caprylic acid at a nonionized concentration (Seng et al. , U.S. Pat. No. 4,939,176); Beta-propionolactone with colloidal silica adsorption (U.S. Pat. No. 4,370,264); combinations of phenol and formaldehyde for inactivating HIV virus in blood and blood components (Louderback, U.S. Pat. No. 4,833,165); mixtures of detergent, alcohol and ether (Prince, U.S. Pat. No. 4,591,505); di- or tri-alkylphosphate and detergent (Neurath et al . ' , U.S. Pat. No. 4,764,369); a variety of techniques using other surfactants (U.S. Pat. Nos. 4,314,997; 4,315,919; and 4,613,501). Chemical sterilization techniques, such as the 1,10-phenanthroline-cuprous ion complex being developed by Cutter Biological, Division of Miles, Inc., Berkeley, CA, are still under development and will probably be plagued by chemical removal, residual toxicities and normal cell damage control (these chemical techniques work by degrading nucleic acids) . A variety of organic solvent techniques with/without the use of detergents has been devised. Treatment with halohydrocarbons is presented in U.S. Patent No. 4,511,556, and various alkanes, ketones and perfluorocarbons are suggested in U.S. Pat. No. 4,490,361. Organic solvent/detergent mixtures (such as ethyl ether/Tween 80, amyl acetate/deoxycholate and tri (n-butyl) phosphate/sodium cholate) are being developed. These techniques are burdened with: processing problems associated with removing the organic solvent and the detergent from the end—product; residual toxic chemicals in the blood plasma proteins and fractions; and ineffectiveness against viruses such as polio with negligible lipid content in their viral coat. UV irradiation, developed during World War II, often fails to remove the infectivity of HBV and pathogens which exhibit very small cross-sections for inactivation; UV irradiation also results in protein denaturation and DNA damage to normal cells. In Europe, UV irradiation is also being used in conjunction with B-propionolactone which is considered a carcinogenic agent. Several companies are developing microfiltration, traditionally used for the removal of bacteria from liquid streams, for virus removal from recombinant-DNA and monoclonal antibody products. Pall Ultrafine Filtration Company has developed a 0.04 micron (40 nanometers (nm)) hydrophilic filter for removing viruses and particles from such products. While this filter has been shown to be effective against viruses ranging in size from 80 to 120 nm, no consistent test has been made available for viruses less than 70 nm in size and very small viruses (such as polio with a diameter of 25 * nm) are not expected to be effectively removed (Toth, C.S.: "Retention of Viral Contaminants by 0.04 micron ND filters," presented at the Engineering Conference, Miami, FL, 1990). Millipore Corporation, Bedford, MA has recently announced (June, 1991) the development of a nonselective filtration system for removing viruses from protein solutions. They claim 4-log removal of viruses greater than or equal to 28 nanometers in size and greater than 7-log removal of retroviruses (100 nanometers) with greater than 90 % recovery of proteins ' with a molecular weight less than 70,000. Millipore also announced that they are developing other membranes for biotherapeutics such as monoclonal antibodies and serum-based products. Some of the problems associated with microfiltration are: ineffectiveness against small viruses; nonspecific adsorption and loss of product; denaturation due to .shear forces; excessive foaming and pore plugging; and difficulty to scale with the most significant disadvantage being the inability to inactivate viruses since a 1 % inefficiency of removal can cause subsequent product contamination. Thus, there still exists substantial difficulty in inactivating viruses in the presence of thermally labile and sensitive proteins without utilizing additives which may be carcinogenic, toxic and/or damaging to biologically active compounds. These additives, which must be removed in a sterile post—process step, place an additional cost and time burden on conventional viral inactivation techniques. Taniguchi et al. described a process for sterilizing plasma powder using treatment with supercritical carbon dioxide. Removal of viruses was never mentioned, and the focus of the reference was on testing for the removal of bacteria. It thus is the principal object of this invention to provide novel methods and equipment for inactivating viruses, especially enveloped or lipid-coated viruses, in proteinaceous products without incurring substantial denaturation. Summary of Invention It has been discovered that critical fluids are effective in inactivating viruses, including viral-like particles but especially enveloped or lipid-coated viruses without substantial denaturation of proteinaceous product and loss of biological activity. The method involves contacting a material with a critical fluid, separating the material from the critical fluid, and isolating the material under aseptic conditions. The material to be treated may be a solid, attached to a solid or in solution and preferably the material is contacted with the critical fluid for a sufficient period of time to render the material substantially virus free. In one preferred application, the material includes desired biological molecules having a desired activity and the material is contacted with the critical fluid under conditions such that the biological molecules substantially retain that activity. Preferred temperatures range from 0.5 Tr to 2.0 Tr (where Tr, the REDUCED TEMPERATURE, is the absolute operating temperature divided by the absolute critical temperature) and most preferably is between 4°C and 40°C. It also is preferable that the material be subjected to the supercritical or near-critical fluids under pressures ranging from 0.2Pr to 20.0 Pr (where Pr, the REDUCED PRESSURE, is the operating pressure divided by the critical pressure) and most preferably in the range of 0.5Pr to lO.OPr. Utilizing a mouse retrovirus as a model for the AIDS virus, it has been demonstrated that the critical fluid viral inactivation process has the potential to inactivate enveloped viruses under remarkably mild conditions. We have also discovered that the process can be operated at relatively low temperatures and for comparatively short residence times with negligible denaturation of blood proteins and other beneficial plasma constituents. e have achieved as much as a 4-log reduction in viral activity in times as short as five minutes. The process is also amenable to continuous flow operation and readily scalable. Potential applications include viral inactivation of plasma and its fractions, serum, recombinant—DNA therapeutics, vaccines and biomedical and research instruments and devices. Novel apparatus also are provided for carrying out the foregoing processes. Brief Description of the Drawing Fig. 1 is a schematic illustration of an apparatus according to the invention. Fig. 2 shows HPLC chromatogramε of various extracts of Baker's yeast using different extraction procedures. Fig. 3. shows HPLC chromatograms of various extracts of Baker's yeast using different extraction procedures. Fig. 4 shows HPLC chromatograms of various extracts of Baker's yeast using different extraction procedures. Fig. 5 is a scanning-electron micrograph showing a yeast cell prior to critical fluid treatment (magnification of 15,600 x) . Fig. 6 is a scanning-electron micrograph showing a single yeast cell after critical fluid treatment (magnification of 20,600x) Detailed Description The invention involves a process for inactivating viruses and other particle-like pathogens using critical fluids. Such particle-like pathogens are intended to be encompassed by the term "virus" herein. By critical fluid it is meant a fluid that is at supercritical conditions. Also included are fluids that are at near (e.g. slightly below) supercritical conditions, and particularly fluids at or slightly below critical temperature and at or substantially above critical pressure. Preferred fluids are those that are gases at ambient conditions and that have critical temperatures of between 0°C and 100°C, most preferably between 0°C and 60°C. When working with biological material (e.g. proteinaceous material), fluids with critical temperatures of substantially less than 60°C (e.g. 40°C) are preferred so as to further preserve biological activity. Preferred fluids includes fluorocarbons such as chlorodifluoromethane, alkanes such as ethylene, propane and ethane, and binary fluids such as nitrous oxide and carbon dioxide. These fluids can be used with small quantities of polar entrainers or modifiers, known in the art as cosolvents. Cosolves include substances such as ethanol, methanol, acetone, and ethylene glycol. Such cosolvents can effect inter alia the polarity of the critical fluid, thereby enhancing the capacity of the critical fluid to exactivate virus in certain materials. The materials to be treated may be any material that can be combined with a selected critical fluid without substantially adversely affecting the material in its arena of intended use. Thus, the material may be a solid, nonorganic material, a solid organic material, a suspension or a solution. The method of the invention is particularly applicable to material having biological activity and particularly to proteinaceous materials attached to a solid support matrix or contained in a solution. Examples include blood plasma, blood plasma fractions, serum used for mammalian cell culture and solutions containing recombinant-DNA derived proteins. The protein even may be contained in living cells although typically the material treated is noncellular. By noncellular it is meant a material that is substantially free of prokaryotic or eukaryotic cells and in particular free of genetically-engineered or hybrid cell lines and the like adapted for producing a biological material of interest. An inconsequential amount of cells may be present in "noncellular" material where, for example. a pretreatment step for removing cells (e.g. centrifugation or cell disruption) has been less than 100% effective. The process also has applicability to the inactivation of viruses and other particle-like pathogens in semi-solid and solid matrices which are labile such as 'foods, spices, pharmaceutical powders and tablets, biomedical devices and membranes such as dialysis membranes. As shown below, different fluids exhibit different degrees of success in inactivating viruses. As will be recognized by one of ordinary skill in the art, a particular fluid will be selected at least based upon at least two factors. Firstly, the fluid selected must be capable of inactivating virus to the desired degree. In certain instances, inactivation of a particular virus may be the goal, and the fluid should be selected accordingly. Secondly, the fluid should be selected such that it does not damage, inactivate or otherwise adversely affect the material being treated in the arena of intended use for that material. For example, in the case of a protein, a fluid having a critical temperature substantially below 60°C and that does not tend to chemically denature the protein or otherwise adversely interact with the protein is preferred. It further will be understood by one of ordinary skill in the art that the particular fluid selected as well as the time of exposure of the critical fluid to the material, the temperature of the mixture and the pressure of the mixture are interdependent and together or individually may determine the appropriate conditions for the desired result. For example, the time of exposure of the material to the critical fluid, may affect the degree of viral inactivation. Thus, conditions for treating the material include those of sufficient time exposure to ensure that the material is substantially free of virus. By substantially free of virus it is meant a reduction in virus below that which is detectable by the procedures described herein. The time of exposure as well as the temperature together may affect the biological activity of a treated, isolated material. In connection with proteins, it is preferred to select conditions such that the desired biological activity of the protein is substantially retained. By substantially retained it is meant that at least 50% of the desired biological activity is retained. As described in the summary, the material is separated from the critical fluid under aseptic conditions. In the case of a solution containing for example a protein, to accomplish separation, the mixture is decompressed thereby resulting in a phase separation of the fluid from the solution containing the proteinaceous product. The material then is isolated under aseptic conditions. By isolating the material it is meant separating the material from the equipment of the invention such as in a sterile bottle or a container (e.g. a flask) or in a package such as a hermetically sealed package. It does not include simply separating the material from the critical fluid into a compartment or container that is part of the sterilization equipment of the invention. It should be understood, nevertheless, that the containers or packages used in isolating the material may be at least temporarily attachable to the equipment of the invention so as to facilitate transfer of the material from the equipment to its isolated state in a sterile container or package. The treated material also may be first collected from the equipment and then filtered such as through a filter to remove bacteria in order to isolate the material under aseptic conditions. The apparatus includes a source of fluid, a high-pressure, recirculation loop, a separation chamber, and at least one low pressure trap. Viral inactivation occurs in the high-pressure recirculation loop, which is rated for continuous operation at 5,000 psig and 100°C. The high-pressure recirculation loop consists of: a chamber 10 into which the material to be treated and the critical fluid are introduced; an injection port 12 for introducing the product into the soaking chamber; a static in-line mixer 14 for continuously mixing the mixture of product and fluid; and a circulation pump 16 for moving the mixture to the in—line mixer 14; .two thermocouples, one associated with the separation chamber (thermocouple Tl) and the other located just upstream of the in-line mixer (thermocouple T2); a pressure indicator P2 also located just upstream of the static in-line mixer; and various interconnecting lines 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36 as well as several process valves PV-3, PV-4, PV-5„ PV-6 and PV-7 for chanelling and controlling the movement of fluid throughout the high—pressure recirculation loop. Critical fluid viral inactivation of a proteinaceous product containing viral contaminants can be conducted in an apparatus such as the one shown in Figure 1, or in other variations of the same adapted to permit a critical fluid to be added to a product, adapted to control pressure, temperature, mixing and residence time, and adapted to separate the critical fluid from the virally inactivated proteinaceous product. Process valves PV-3, PV-5, PV-6 and PV-7 are all 1/4 " full-opening two-way Stainless Steel ball valves rated for 6,000 psig at 100C (Parker, Huntsville, Alabama); PV-4 is a three-way stainless steel ball valve (Parker, Huntsville, Alabama). In some embodiments of the invention, process valve PV-7 is a back-pressure regulator (Model No. 26-1722-24, Tescom Corporation, Elk River, Minnesota) with which the operator can control the decompression of the separation chamber and the high pressure circulation loop. The particular soaking chamber 10 employed was a high pressure stainless steel vessel having ' a capacity of 150 ml and an operating pressure of 5,000 psig at 100C (Model Z148, Hoke Inc., Cresskill, New Jersey) . A K-type thermocouple Tl was placed in contact with the outer surface of the soaking chamber 10 and the temperature monitored on a digital temperature-indicator-controller (Model No. CN-310KC, Omega Engineering, Inc., Stamford, Connecticut). The soaking chamber 10 has a top inlet line 18 and a bottom outlet line 20. The inlet line 18 communicates at a fluid joint with the source of critical fluid, the product injection port 12, and the outlet line 22 of the static in-line mixer 14. The outlet line 20 of the soaking chamber 10 and one end of conduit line 24 are connected at a fluid joint which joint in turn is connected to the decompression valve PV-7. The other end of conduit line 24 is connected at a fluid joint to the inlet line 26 of the circulation pump 16. The particular circulation pump 16 used was a variable speed (0 to 9,000 rpm) , high pressure (5,000 psig at 150C) gear pump capable of a flowrate of 300 ml/min at a pressure differential of 10 to 20 psig (Modified Model No. 183, custom-built by Micropump,Concord, California) . The circulation pump 16 had a cooling head made of an aluminum block connected to a circulating, refrigerated water bath capable of maintaining temperatures as low as 5C and a cooling rate 15,300 Btu/h (Model No. HX-150, Neslab, Inc., Concord, New Hampshire). The discharge line 28 of circulation pump 16 is connected at a fluid joint to one end of the conduit line 30, which joint in turn is connected to drain valve PV—6. The other end of conduit line 30 is connected at a fluid joint to the inlet line 32 of the static in-line mixer 14 which joint in turn is connected to vent valve PV-5. Conduit 30 has an in-line pressure indicator P-2 and an in-line K-type thermocouple T2 which is connected to a temperature-indicator controller (Model No. CN-310KC, Omega, Stamford, Connecticut) . The particular static in-line mixer 14 employed was a 3/16 " ID x 7 1/2 " long x 27 element tube mixer rated for 4,642 psig at 300F (Kenics Mixer Model No. 37-03-075, Chemineer, Dayton, Ohio). The outlet line 22 of the static in—line mixer 14 and the inlet line 18 to the separation chamber 10 are connected at a fluid joint. This joint is connected to critical fluid feed valve PV-3 and also is connected to the three-way process valve PV-4. The three-way process valve PV—4 allows fluid connection between the injection port 12 and either the recycle conduit 34 or the inlet line 18 of the soaking chamber 10. The recycle conduit at its other end is connected to the joint between the conduit line 24 and inlet 26 of the circulation pump 16. The critical fluid is in fluid communication with feed valve PV-3 via a series of conduit lines interrupted by valves, pumps and filters. Release of critical fluid from the container 36 is controlled by valve PV-1 on the head of the high pressure container. The fluid is conducted from the container 36 to the inlet of compressor 38 via conduit line 40. The particular compressor employed was a single-ended diaphragm compressor which can compress gas or liquid up to 10,000 psig at a flow rate of 40 standard liters per minute (Model No. J-46-13411, Superpressure Gas Compressor, Newport Scientific, Jessup, Maryland). A process valve PV-2 is connected to the outlet of the compressor 38 and can be closed when the desired pressure is achieved. The fluid is conducted from the compressor 38 to a pair of in-line filters 42, 44 via conduit line 46. The particular in-line filters used were a 7 micron sintered stainless steel cup filter 42 (Model No. SS-8F-K4-7 in a 6TF stainless steel housing, Nupro Company, Willoughby, Ohio) and a 0.5 micron sintered stainless steel cup filter 44 (Model No. SS-8F-K4-05 in a 6TF stainless steel housing, Nupro Company, Willoughby, Ohio) . The fluid exits the outlet of filter 44 and is conducted via conduit 48 to valve PV-3. The high pressure recirculation loop interfaces with the product recovery, low pressure half of the apparatus which is made up of a 500 ml decompression chamber 50, a first low pressure trap 52, and several two-way valves and connecting lines. The exhaust system consists of a second low pressure trap 54 leading to a vent line which exhausts to the atmosphere. In other embodiments of this invention, the vented critical fluid is first filtered and then recycled to the inlet of the compressor P-l. The mixture in the soaking chamber 10 can be moved through the outlet line 20 via decompression valve PV—7 to a decompression tube 56 which extends to within about 1/4" of the bottom of decompression chamber 50. The decompression chamber 50 has one inlet through which decompression tube 56 is inserted and sealed, and two outlet lines. The bottom outlet line 58 exits the bottom of the chamber 50 and is connected to process valve PV-8 (same type as PV-2) which in turn is connected to a sample port 60 for the recovery of liquid solvents and slurries. The top outlet line 62 exits the top of the decompression chamber 50 and is connected to low pressure trap 52. The particular decompression chamber employed was a 500 ml stainless steel high pressure chamber rated for 5,000 psig at 100C (Model No. Z152, Hoke Inc., Cresskill, New Jersey). The low pressure trap 52 has one inlet 64 through which the top outlet line 62 of the decompression chamber 50 is inserted and sealed. It also has two outlet lines. The bottom outlet line 66 exits the bottom of the low pressure trap 52 and is connected to process valve PV-9 which in turn is connected to a sample port 68 for the recovery of any liquid solvents and slurries carried over during the decompression process. The top outlet line 70 exits the top of low pressure trap 52 and is connected to a second low pressure trap 54. The second low pressure trap 54 has one inlet 72 through which the top outlet line 70 of low pressure trap 52 is inserted and sealed and two outlet lines. The bottom outlet line 74 exits the bottom of the second low pressure trap 54 and is connected to process valve PV-10 which is connected to a sample port 76 for the recovery of any liquid solvents and slurries carried over during the decompression process. The top outlet line 78 exits the top of second low pressure trap 54 and is vented to atmosphere. The particular low pressure traps employed were 150 ml high pressure Monel chambers rated for 5,000 psig at 100C (Model No. Z152, Hoke Inc., Cresskill, New Jersey). For reasons of safety and equipment flexibility, the product recovery half of the apparatus was also designed for continuous operation at a pressure of 5,000 psig at 100C. Both the high pressure circulation loop and the product recovery half of the apparatus are enclosed in a polycarbonate (Lexan) box 80 which serves as a containment chamber. This chamber is heated by a 1500W (Pelonis) heater 82 and controlled by a solid state ON-OFF temperature-indicator-controller 84 (Model No. CN-310KC, Omega, Stamford, Connecticut) based on the in-line temperature T2 in conduit 30 attached to the discharge line 28 of the circulation pump P-2 16. As an initial condition, the system is cleaned, sterilized and dried, and is at operating temperature (room temperature to 40C) with all process valves (PV) in the closed position. To accomplish this, the system was rinsed with 0.5mM EDTA in order to complex and remove any metal traces on the inside of the apparatus. The system was sterilized by filling with 70% ethanol solution via the 7 micron and the 0.5 micron filter elements. The system was then heated to 40C and the ethanol circulated in the high pressure circulation loop of the apparatus for about 30 minutes. The blowdown valve PV-7 was then opened and the entire system filled with 70% ethanol to the vent valve after LPT-2. All valves, namely PV-4, PV-5, PV-6, PV-8, PV-9 and PV-10, were bled until ethanol was seen. Valves PV-4 and PV-6 were covered with gauze soaked in 70% ethanol and then covered with aluminum foil. The system was held at 40C for approximately 30 minutes. The ethanol was then displaced from the system with pressurized (around 100 psig) and filtered (through the 7 micron and 0.5 micron filters) nitrogen through valves PV-6, PV-8, PV-9 and PV-10. When liquid was no longer coming out, these valves were all covered with ethanol soaked gauze and aluminum foil. The entire system was then rinsed with 0.2 micron filtered distilled and deionized (DDI) water. All valves were bled and the water displaced out of the system using filtered nitrogen under pressure. The sample loading tube, collection flasks and the fill bell (with silicon tubing attached) were all sterilized in an autoclave set at 250F for 30 minutes on fast exhaust. The loading tube was wrapped in gauze; about 2 ml of DDI water (in order to generate steam) was placed in the flasks which had a gauze and cotton plug covered with aluminum foil. When the steam cycle was completed, a 20 minute drying cycle was conducted. In its normal operating mode, valves PV-4 and PV-5 are opened and an aliquot of test solution is aseptically introduced through the 3-way valve PV-4 using a sterile syringe and a presterilized loading tube. The 3-way valve PV-4 is then turned so that the critical fluid recycle line communicates with the soaking chamber, and the vent valve PV-5 is closed. PV—l is then opened, supplying the solvent to the compressor P—1. The compressor is turned on and immediately thereafter valves PV—2 and PV-3 are opened, introducing the critical fluid solvent into the high pressure circulation loop. When operating pressure is attained, the compressor is turned off and valve PV-3 is closed. After system stabilization, the circulation pump P-2 is turned on and its speed adjusted, typically to 75 % of maximum speed or 6,750 rpm. P-2 draws both the proteinaceous product from the bottom of the soaking chamber and the critical fluid phase from the top of the same unit. The mixture is then pumped counter-clockwise, mixed by static in-line mixer and returned to the soaking chambe . Af er mixing for a defined residence time, P-2 is turned off. The decompression valve PV-7 is then fully opened to depressurize the soaking chamber and the high pressure circulation loop. The rate of decompression waε approximately 500 psi per second when PV-7 is a 1/4" ball valve. By using a back—pressure regulator instead of a 1/4" ball valve as the decompression valve PV—7, the rate of decompression can be controlled. In some experiments, the rate of decompression was controlled to approximately 1,000 psi per minute. No differences were observed between rapid (500 psi per second) and slow (1,000 psi per minute) rates of decompression on the impact of critical fluid on viral infectivity and product activity. The* experiments in Example 1 below were conducted with slow decompression while the experiments in the remaining examples presented below were conducted with rapid decompression. After decompression, product was aseptically collected into a sterile flask from the decompression chamber 50 through sample port 60 which was aseptically connected to _a sterile fill bell. The collected sample was stored on ice until assayed. In the examples described herein, samples of a recombinant murine C-type retrόvirus were prepared as follows. The cell line Psi-2 (Mann et al . , 1983, Cell 33:153-159), which produces defective Moloney murine leukemia virus particles (particles that lack viral nucleic acid, but are otherwise wild type) , was transfected with plasmid DNA consisting of the retrovirus vector LNCX (Miller and Rosman, 1989, Biotechniqueε 7:980-990) that had previously been modified by the insertion of a chimeric beta-tubulin gene (Bond et al. , 1986, Cell 44:461-468) into the Stu 1 site of the LNCX vector. Clonal cell lines stably expressing the transfected DNA were derived and maintained as virus-producing stockε. By packaging the RNA produced by the tranεfected DNA into the defective particles, these cells produce infectious particles that are entirely normal with respect to overall structure, stability, and mode of infection, but containing the plasmid-derived rather that the wild type, genetic material (Mann et al.. Ibid) . Because the LNCX sequences contain the antibiotic resistance gene neo and a suitable promoter, infection of cells with the recombinant retrovirus confers upon the cells resistance to the antibiotic Geneticin (G418) . Conferral of Geneticin-resistance onto cells and their progeny was therefore used as the property by which virus titers were determined. Specifically, virus stocks were prepared by culturing the virus-producing cells at high density (50% confluence) in fresh culture medium (Dulebecco's modified Eagle's medium supplemented with 10% iron-supplemented calf serum [Hyclone, Inc., Logan, UT] , glutamine [1 mM] , penicillin [100 U/ml] and streptomycin [100 μg/ml]) for 18 hours at 37C in a humidified 5% C02 atmosphere. Culture medium was harvested and passed through a 0.2 micron filter, divided into aliquots, quick frozen using a dry-ice/ethanol bath and stored at -80C. Immediately before use, samples were warmed in a 37C water bath until just thawed and held on ice. Aliquots of a single virus preparation were used for the examples described below. After virus-containing sampleε were mixed with other materials and treated as described in each of the examples, they were returned to ice, and assayed within 8 hours. Titer tests were performed by seeding 35 mm-style culture dishes with a mouse fibroblast line (NIH3T3 cells) in 3 ml of the culture medium described above at a density of 10,000 cells per well the evening before the assay was to be performed. Virus samples were added to the culture medium over the cells at various dilution from 10 (undiluted) to 10- . In some cases (where indicated) , polybrene (Aldrich Chemical Co.) was added along with virus at a final concentration of 2 μg/ml. Polybrene is a polycation that enhances the infectivity of retroviruses up to lOO-fold, apparently by enhancing the adsorption of viral particles to cell surfaces; polybrene is commonly used in assaying mouse retroviruε titers. After addition of virus, test cells were returned to the incubator overnight, and then washed into fresh medium containing 1 mg/ml Geneticin. This medium was replenished 2-3 times over the following two weeks, after which the plates of cells were fixed (with 10% formalin in phosphate-buffered saline) , stained with Coomasεie Blue dye, washed in 25% ethanol, and air-dried. During the two weeks of growth, each virus-infected cell gives rise to a colony of Geneticin-reεiεtant cells. Because the LNCX-genome does not encode the functions necessary to produce new virus particles, virus-infected particles do not spread infection to nearby cells. Therefore, all cells not infected during the initial overnight exposure to the virus remain sensitive to the antibiotic, and die during the two week incubation. Consequently, the number of colonies (as visualized by Coomassie blue staining) present at two weeks provides an accurate reflection of the number of -infectious virus particles initially applied to the cells. In parallel with all examples shown, control experiments were performed to demonstrate that cells not exposed to virus produced no colonies at two weeks, and cells exposed to untreated virus produced the expected number of colonies. As a result of our experiments, including those described in the examples below, we have discovered that critical fluids can be toxic to viruses. The cause of toxicity has not yet been determined but may involve any of at least four possible mechanisms: Extraction of Viral Components: Critical fluids are excellent solvents. They can exhibit a liquid-like denεity and, at the εame time, gas-like properties of diffusivity, viscosity and surface tension. The critical fluids may be penetrating cells and subcellular structures (exhibiting solubilization properties similar to those of organic liquids) . For example, supercritical carbon dioxide at 3,000 psig and 40C has a density of 0.8 g/cc and behaves like an organic solvent with the diffusivity of a gas. Critical fluids have additional degrees of freedom over organics in that solvation capacity can be readily adjusted by changing density (via changes in temperature and/or pressure) , and selectivity can be altered by the type and concentration of polar entrainers such as an alcohol. One virus component that might be disrupted by critical fluids is the viral envelope, which contains cell derived lipidε. Preliminary studies with yeast cells (see Figure 2) suggest that critical fluids are indeed very effective at phospholipid extraction from biological sampleε. Figure 2a showε an HPLC chromatogram of a hexane-isopropanol extract of untreated Baker ' ε yeast feedstock; the major phospholipid peaks are clearly defined, having been identified and quantified by the use of standards. Figure 2c showε that supercritical nitrous oxide (SCF N20) is very effective in liberating several phospholipids from Baker's yeast. Figure 2b shows that supercritical nitrogen (SCF N2), a control solvent at identical conditions of pressure, temperature and time, is relatively ineffective for the liberation of phospholipids from Baker's yeast. Explosive Decompression: Upon depressurization, critical fluids exhibit large specific volume changes. For example, supercritical carbon dioxide will expand by a factor of approximately 400 fold when depressurized from 3,000 psig and 40C to atmospheric conditions. When depressurization is sufficiently rapid, explosive decompressive forces may play a role in disrupting microscopic structures. This phenomenon is demonstrated in Figure 3 in which yeast cells were exposed to the critical fluid viral inactivation process, using the apparatus depicted in Figure l. The top scanning electron micrograph showε a εingle yeast cell before treatment (a magnification of 15,600X), while the bottom plate showε a yeaεt cell after treatment (a magnification of 20,600X). Disruption of the normally rigid yeast cell wall is apparent. It is possible that such explosive forces also participate in the inactivation of viruses, which are considerably smaller than yeast, but direct evidence haε not yet been obtained. Virus Particle Disintegration: The components of viruses (proteinε, nucleic acid, and sometimes lipid) self-assemble inside cells to produce infectious viral particles. Noncovalent forces of protein aggregation are primarily responsible for holding these particles together. Under conditions of very high pressure (e.g. 20,000 psig and higher), protein-protein and protein-lipid interactions can be disrupted. Thus, it is possible that viral particles undergo partial or total disassembly under the conditions that we have used. Chemical Modification: Under atmospheric conditions, most viruses are chemically quite stable. Under conditions of high presεure and in the preεence of critical fluids, however, chemical reactions might occur that do not normally do so under atmospheric conditions at a significant rate. Examples of such reactions might be the oxidation of lipids (perhaps catalyzed by nitrous oxide) , or the hydrolysis or chemical modification of nucleic acids, both of which might interfere with viruε function. Chemical reactions involving proteins might also occur, although the remarkably mild effects of the viral inactivation process on bovine plasma (see below) suggest that proteins are relatively unaffected by the process. In addition to demonstrating that critical fluids can be toxic to viruses, we have examined the impact of the critical fluid viral inactivation process on biologically active proteins and small molecules. If critical fluid inactivation iε to be useful in destroying viruses in biological sampleε such as blood plasma, cell culture media, pharmaceutical substanceε, and substances derived using recombinant DNA techniques, the process must be relatively harmlesε to the beneficial components of those subεtanceε. Proteinε are of the greateεt concern in this regard, because these molecules are susceptible to denaturation by a host of factors including temperature, extremeε of pH and ionic εtrength, drying, exposure to nonaqueous liquidε or detergentε, and even mechanical shear. During the conduct of research on several other bioseparation processeε utilizing critical fluidε, we have subjected several natural and recombinant—DNA proteins to a variety of critical fluids under different conditions. In one particularly revealing study conducted in collaboration with a biopharmaceutical company, a recombinant-DNA growth hormone of commercial importance was treated with supercritical fluids and its activity meaεured by a very precise HPLC technique (which is approved by the FDA and the WHO) . Our data indicates that there were no detectable changes in activity and structural conformation of the protein tested (under conditions which are very similar to those in the examples given below) . We have observed that supercritical carbon dioxide is not a good candidate for liquid media systems because of acid pH effects. Other than this negative impact on proteins, we have not detected any significant changes in biological activity by critical fluids over a wide range of pressure (0 to 10,000 psig) . In order to demonstrate that the conditions necesεary for viral inactivation are not exceedingly harmful to the beneficial constituents of proteinaceous productε, several experiments were conducted and are reported in Examples l, 2, 3 and 4 below. Similar conditions were then utilized to inactivate viral particles in the presence of different levels of proteins; these experiments are reported in Examples 5, 6 and 7 below. Examples of our diεcloεure are given below to εhow how variableε such as critical fluid type, cosolvent concentration, temperature, pressure and time can effect reduction in viral activity and biological activity. It should be understood that the critical fluid viral inactivation process is not limited to the following exampleε which are preεented to further illustrate the invention. EXAMPLE 1 IMPACT OF SUPERCRITICAL CARBON DIOXIDE AND NITROUS OXIDE ON BOVINE PLASMA In order to evaluate if critical fluid treatment would adversely affect the beneficial constituents of plasma, several experiments were carried out with bovine plasma. Aseptically collected bovine blood treated with an anticoagulant (sodium citrate) waε centrifuged at a εpeed of 3,000 rp for 30 minuteε in a refrigerated centrifuge at IOC. 75 ml of the decanted plasma was introduced into the apparatus shown as Figure 1, contacted with the critical fluid at the conditions listed in the top half of Table 1 and then εlowly decompreεεed to atmoεpheric conditionε. In this series of experiments, there were two controls — CFI-0 which is the untreated, unprocesεed plasma, and CFI—3 which is processed in the critical fluid viral inactivation (CFI) apparatus without critical fluids. The latter control accounts for the mechanical impact of mixing on proteins and other beneficial constituents. The recovered sampleε were spun down in a refrigerated centrifuge at 3,000 rpm for 30 minutes at 10C; the clarified plaεma waε then sent out to Tufts University Veterinary Diagnostic Laboratory, Boston, MA for analysiε. The reεultε of thiε analysis, summarized in the bottom half of Table 1, indicate that supercritical carbon dioxide had an adverse impact on the beneficial constituents of the bovine plasma, namely alkaline phosphatase (AKP), lactic dehydrogeήase (LDH) and creatine phosphokinaεe (CPK) , while the impact of supercritical nitrous oxide was much less severe. TABLE 1 IMPACT OF CRITICAL FLUID CARBON DIOXIDE AND NITROUS OXIDE ON BOVINE PLASMA PARAMETER CFI-0 CFI-1 CFI-2 CFI-3 Critical Fluid C02 N20 Pressure (psig) — 4,000 4,000 Temperature (C) 4 40 40 40 Time (mins) — 30 30 30 BUN - Blood Urea Nitrogen AKP - Alkaline Phosphataεe LDH - Lactic Dehydrogenaεe CPK - Creatine Phosphokinaεe EXAMPLE 2 IMPACT OF PRESSURE ON CRITICAL FLUID NITROUS OXIDE ON BOVINE PLASMA The second set of runs waε conducted with supercritical nitrous oxide at different presεureε. Within 24 hours after treatment, a SMAC analyεiε was performed on the recovered plasma by Bioran Laboratories, Cambridge, MA. All SMAC results were repeated and verified by Bioran Laboratories. The conditions of these runs and the reεultε of the analysis are listed in Table 2. At the end of the experimentε, the mixture of critical fluid and bovine plasma was rapidly decompresεed (at a rate around 100 psig/sec) and the critical fluid separated from the now treated plasma. The results listed in Table 2 indicate that supercritical nitrous oxide had little or no impact on blood urea nitrogen (BUN), AKP, LDH, albumin, triglycerides and choleεterol over the range of pressures tested, and there waε little or no εenεitivity to the level of pressure between 1,000 and 3,000 psig. It should be noted that the glucose values for experiments CFI-4 through CFI-7 are about twice that of the control CFI-00. Theεe results are difficult to fathom since the glucose level of bovine plasma treated with SCF N20 at 4,000 psig and 40C waε about the same as the control in the firεt example (see Table 1). The higher glucose levels could have been caused by the critical disruption of red blood cells which were not removed in the plaεma preparation. TABLE 2 IMPACT OF PRESSURE ON CRITICAL FLUID NITROUS OXIDE ON BOVINE PLASMA PARAMETER CFI-00 CFI-4 CFI-5 CFI-6 CFI-7 Critical Fluid N20 N20 N20 N20 Preεεure (psig) 1,000 2,000 3,000 Temperature (C) 4 40 40 40 40 Time (mins) 30 30 30 30 Glucose (mg/dl) 77 148 149 155 153 BUN (mg/dl) 18 16 15 16 16 Protein (g/dl) 7.7 6.3 5.9 6.4 6.5 AKP (U/l) 24 30 30 34 35 LDH (U/l) 1,111 891 767 883 891 Albumin (g/dl) 2.5 2.4 2.4 2.6 2.5 Triglycerides (mg/dl) 11 16 17 18 17 Cholesterol (mg/dl) 143 148 136 150 154 BUN - Blood Urea Nitrogen AKP - Alkaline Phosphatase LDH - Lactic Dehydrogenaεe CPK - Creatine Phosphokinase EXAMPLE 3 IMPACT OF CRITICAL FLUID TYPE ON BOVINE PLASMA In thiε series of experimentε, the critical fluid was varied; with the exception of the control — CFI-00 — procesε conditionε were 3,000 psig, 40C and 30 minutes.. The critical fluids tested were nitrous oxide (N20) , ethylene (C2H4), ethane (C2H6), propane (C3H8), tri-fluoromethane (CHF3 or Fr-23), chlorodifluoromethane (CHC1F2 or Fr-22) . The conditionε of theεe experimentε and εome relevant thermo-dynamic propertieε are liεted in the top half of Table 3. These solvents, with the exception of propane and Freon-22, are all supercritical at the tested conditionε of 3,000 pεig and 40C. The reεults of explosive decompression experiments with these critical fluidε and bovine plasma are listed in the bottom half of Table 3. These results can be compared against values for the control in Table 2. Apart from the doubling of glucose concentration levelε and εome detrimental effectε on LDH in CFI-7 through CFI-12, the first six critical fluids tested in Table 3 had a negligible impact on blood constituents. Near-critical Freon-22 and supercritical Freon-23 had the most significant impact on LDH decreasing concentration by slightly more than 50% of the original value. TABLE 3 - IMPACT OF CRITICAL FLUID TYPE ON BOVINE PLASMA PARAMETER CFI-7 CFI-8 CFI-9 CFI-10 CFI-11 CFI-12 CFI-13 Critical Fluid N20 C2H4 C2H6 C3H8 Fr-23 Fr-22 N2 Crit. Press. (psia) " 1,051 731 709 616 701 722 493 Crit. Temp.(C) 36.4 9.2 32.2 96.6 25.9 96.0 -147.0 Presεure (pεig) 3,000 3,000 3,000 3,000 3,000 3,000 3,000 Temperature (C) 40 40 40 40 40 40 40 Time (mins) 30 30 30 30 30 30 30 Glucose (mg/dl) 153 157 156 161 166 132 68 BUN (mg/dl) 16 17 16 17 16 16 12 Protein (g/dl) 6.5 6.8 6.9 7.1 6.4 6.5 6.6 AKP (U/l) 35 34 33 35 26 24 24 LDH (U/l) 891 808 837 907 522 510 971 Albumin (g/dl) 2.5 2.7 2.5 2.6 2.7 2.8 2.3 Triglycerideε (mg/dl) 17 19 18 18 30 29 11 Choleεterol (mg/dl) 154 154 152 152 124 134 128 BUN - Blood Urea Nitrogen AKP - Alkaline Phosphatase LDH - Lactic Dehydrogenase CPK - Creatine Phosphokinase EXAMPLE 4 IMPACT OF RESIDENCE TIME AND OPERATING TEMPERATURE ON THE CRITICAL FLUID TREATMENT OF BOVINE PLASMA The impact of residence time and operating temperature on some of the beneficial constituents of bovine plasma treated by SCF N20 at 3,000 psig is listed in Table 4. The data suggeεts that temperature more than time had an impact on SCF N20 treated bovine plasma. For example, both CFI-14 and CFI-15 which were conducted at 30C had negligible impactε on glucose, total protein and LDH verεus CFI-7 which waε conducted at 40C. Also, there was no εignificant difference in the impact of CFI-14 and CFI-15 which had residence times of 30 and 5 minutes. TABLE 4 IMPACT OF RESIDENCE TIME AND OPERATING TEMPERATURE ON THE CRITICAL FLUID TREATMENT OF BOVINE PLASMA BUN - Blood Urea Nitrogen AKP - Alkaline Phoεphataεe LDH - Lactic Dehydrogenase CPK - Creatine Phosphokinaεe EXAMPLE 5 IMPACT OF RESIDENCE TIME ON CRITICAL FLUID VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN CULTURE MEDIUM Several teεtε were conducted with 30 ml of culture medium containing murine C-type retroviruεeε and supercritical nitrous oxide at approximately 3,000 psig and 40C. These experimentε (CFI-18, CFI-19, and CFI-20 liεted in Table 5) were conducted at different residence times ranging from 5 to 121 minutes; CFI-21 in Table 5 was conducted with supercritical nitrogen at similar conditions of temperature and pressure for 30 minutes. Between each run, and as described above, the experimental apparatus was rinsed with sterile deionized water, sterilized with 70 % ethanol through 7 and 0.5 micron filters, and again rinεed with sterile deionized, distilled water; the apparatus waε then dried with filtered compreεεed nitrogen or air. After each experiment, the recovered εamples were halved; one half waε εpun down at 2,500 rpm for 10 minutes and the supernatant subjected to 0.45 micron filtration. Titer testε, ability to infect 3T3 fibroblasts and confer G418 resistance, were conducted on duplicate 2.3 ml sampleε at six different dilutions. The appropriate titerε of recovered εampleε are listed in Table 5 and shown as a function of residence time in Figure 4. The reεultε indicate that supercritical nitrogen was relatively ineffective in inactivating the retrovirus whereas supercritical nitrouε oxide was very effective in inactivating the retrovirus. The supercritical nitrogen resultε can be correlated with itε inability to solubilize/liberate phospholipidε as εhown in Figure 3. On the other hand, εupercritical nitrous oxide rapidly inactivated the retrovirus in a period between 30 and 121 minutes. TABLE 5 IMPACT OF RESIDENCE TIME ON CRITICAL FLUID VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN CULTURE MEDIUM * Detection limit EXAMPLE 6 IMPACT OF CRITICAL FLUID TYPE AND COSOLVENT ON THE VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN SERUM Several critical fluid viral inactivation experiments were conducted with murine-C retrovirus in serum. Proteins are known to have a protective effect on the viability of viruses. These experiments were thus conducted to evaluate the effectivenesε of the critical fluid viral inactivation technique in a protein—rich medium. Murine-C retroviruε in culture medium was mixed 50/50 with serum (εerum waε a 50/50 mix of Hyclone fetal bovine εerum and Hyclone iron supplemented calf serum) and divided into 5 equal aliquots. Experimentε were conducted with εeveral critical fluidε — nitrous oxide (N20) , a nitrous oxide/2 mole % ethanol mixture, chloro- difluoromethane (CHC1F2 or Fr-22) and propane (C3H8) at approximately 3,000 psig and 40C for a residence time of 30 minutes. One critical fluid experiment (CFI-26) was conducted at 60C. These experiments are listed in Table 6. Several controls were conducted on samples which were not treated with critical fluids — one at 40C, one at 40C with 2 mole % ethanol in the serum, and one at 60C. Titers were run on controlε and recovered εampleε without polybrene enhancement (in duplicate at εix dilutions) and with polybrene enhancement (in duplicate at four dilutions) . The titer results indicate that 2 mole % ethanol does not affect the titer but that heating at 60C does deεtroy the retroviruε. The titer results presented in Table 6 are for polybrene enhanced determinations (theεe valves are consiεtent with titerε determined without polybrene). The 40C control had a titer of 65,000 cfu/2.3 ml. The reεults listed in Table 6 indicate that the presence of protein did reduce the effectiveness of supercritical nitrous oxide by one to two orders of magnitude (compare CFI-27 in Table 6 to CFI-18 in Table 5). Alεo, 2 mole % ethanol had little or no impact on the effect of εupercritical nitrouε oxide. Freon-22, however, had a εignificant impact on murine-C retroviruε, reducing viral activity by some 3.2 log orders of magnitude after 30 minutes of contacting the serum. TABLE 6 IMPACT OF CRITICAL FLUID TYPE AND COSOLVENT ON THE VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN SERUM PARAMETER Control CFI-26 CFI-27 CFI-28 CFI-29 CFI-30 Critical Fluid N20 N20 N20/EtOH Fr-22 C3H8 Pressure (psig) 3,000 3,000 3,000 3,000 3,000 Temperature (C) 40 60 40 41 41 41 Time (mins) - • — 30 30 30 30 30 Titer 65,000 < 5* 3,000 5,000 40 2,500 (cfu/2.3 ml) - loglO Reduction N/A > 4.1 1.4 1.1 3.2 1.4 * Detection limit EXAMPLE 7 IMPACT OF RESIDENCE TIME, CRITICAL FLUID TYPE AND PRESSURE ON THE VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN SERUM Based on the results in Example 6, several experimentε were conducted with Freon-22 at approximately 3,000 pεig and 40C to determine the impact of residence time on viral reduction capability. The experiments, listed in Table 7, indicate that Freon-22 can, within the detection limits of the assay, eliminate viral activity within five minutes. This example also indicateε that preεεure haε a εignificant impact on the effectiveneεs of critical fluid viral inactivation. CFI-34 in Table 7 indicate that supercritical nitrous oxide at 5,000 psig and 40C for a residence time of 30 minutes inactivated the entire viral population (within the detection limits of the assay), while CFI-27 in Table 6 shows that supercritical nitrous oxide at 3,000 psig and 40C for a residence time of 30 minutes reduces virus activity by only 1.4 logs. TABLE 7 IMPACT OF RESIDENCE TIME, CRITICAL FLUID TYPE AND PRESSUREON THE VIRAL INACTIVATION OF MURINE-C RETROVIRUS IN SERUM PARAMETER Control CFI-31 CFI-32 CFI-33 CFI-34 CFI-35 Critical Fluid Fr-22 Fr-22 Fr-22 N20 N2 Pressure (psig) 3,000 3,000 3,000 5,000 3,000 Temperature (C) 40 40 40 41 41 41 Time (mins) 5 15 60 30 60 Titer 20,000 < 5* 5 < 5* < 5* 3,750 (cfu/2.0 ml) -loglO Reduction N/A > 3.6 3.6 > 3.6 > 3.6 0.7 * Detection limit RKb'ERENCES Castor, T.P. and Hong, G.T. : "Supercritical Fluid Disruption of and Extraction from Microbial Cells," U.S. Patent Application serial no. 07/799,767, filed November 25, 1991, the entire discloεure of which iε incorporated herein by reference. Bond, J.F., Fridovich-Keil, J.L., Pilluε, L., Mulligan, R.C. and Solomon, F. : "A Chicken-Yeast Chimerica Beta-Tubulin Protein Is Incorporated into Mouse Microtubules In Vivo", Cell, Vol. 44, 461-468, 1986. Charm, S.E., Landau, S., Williams, B., Horowitz, B., Prince, A.M. and Pascual, D.: " "High Temperature - Short Time Heat Inactivation of HIV and other Viruses in Human Blood Plasma," supported in part by NHLBI Grant No. HL41221 to the New York Blood Center, Nov. 16, 1990 and accepted for publication in Vox Sanguinis, 1991. Mann, R. , Mulligan, . R. and Baltimore, D.: "Construction of a Retroviruε Packaging Mutant and its Use to Produce Helper-Free Defective Retrovirus," Cell, Vol. 33, 153-159, 1983. Miller, A.D. and Rosman, G.J. : "Improved Retroviral Vectors for Gene Transfer and Expression," Biotechniques, Vol. 7, 980-990, 1989. Morgenthaler, J.J. : Virus Inactivation in Plasma Products, in Current Studieε in Hematology and Blood Tranεfuεion, Eds. A. Hassig and P. Lundsgaard-Hanεen, Karger, New York, 1989. Taniguchi, M. , Suzuki, H. , Sato, M. and Kobayaεhi, T.: "Sterilization of Plasma Powder by Treatment with SCF C02," Aqric. Biol■ Chem. , 51 (12), 3425-3426, 1986. Toth, C.S.: "Retention of Viral Contaminants by 0.04 micron ND filters," presented at the Engineering Conference, Miami, FL, 1990. Given the above disclosure and examples, variations and equivalents will be readily apparent to those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is intended that the exampleε be for illuεtration purposes only; variations and equivalents are intended to be included within the scope of the following claims.

Claims: We claim : 1. A method for inactivating virus asεociated with a material compriεing contacting the material with a critical fluid under conditions, separating the material from the critical fluid under conditions, and isolating the material under aseptic conditions. 2. A method for inactivating virus as claimed in claim 1 wherein the material iε contacted with a critical fluid for a εufficient period of time to render the material substantially virus free. 3. A method for inactivating virus as claimed in claim 1 wherein a material that is noncellular and proteinaceous is contacted with the critical fluid. 4. A method for inactivating virus as claimed in claim 3 wherein a material that iε in solution iε contacted with a critical fluid. 5. A method for inactivating virus as claimed in claim 1 wherein a material that is a εolid iε contacted with the critical fluid. 6. A method for inactivating virus as claimed in claim 5 wherein the material is contacted with a critical fluid for a ε fficient period of time to render the material substantially virus free. 7. A method for inactivating virus as claimed in claims 1, 2, 3, 4, 5 or 6 wherein the material includes desired biological molecules having a desired activity and wherein the material is contacted with the critical fluid under conditions εuch that the biological molecules substantially retain that activity. 8. A method for inactivating virus as claimed in claims 1, 2, 3, 4, 5 or 6 wherein the material is contacted with a critical fluid at below 60°C. 9. A method for inactivating virus as claimed in claims, 1, 2, 3, 4, 5 or 6 further comprising subjecting the mixture of material and critical fluid to near critical pressure or higher while maintaining the mixture at or near critical temperature.

Inventors: CASTOR TREVOR P, LANDER ARTHUR D, CASTOR, TREVOR, P., LANDER, ARTHUR, D.
Applicants: BIOENG INC, BIOENG, INC.
Application year: 1993
Main classification: A61L2
IPC codes: A61L2, C12N7